VF
SKYE icon

Virtu Financial’s Skye Bioscience SKYE Stock Holding History

Virtu Financial’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,626
Closed -$21K – 2129
2025
Q1 		$21K Buy
1,626
+358
+28% +$7.82K ﹤0.01% 1102
2024
Q4 		$29K Buy
+1,268
New +$42.4K ﹤0.01% 1244

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Virtu Financial's SKYE Position: Q2 2025 in Review

Virtu Financial sold out of Skye Bioscience (SKYE) in Q2 2025, closing a stake of 1,626 shares — an estimated $21K sold.

Virtu Financial first reported a position in SKYE in Q4 2024 and held it in 2 quarters. The position peaked at $29K in Q4 2024. 55 funds tracked by Wall St. Rank hold SKYE as of Q2 2025.

  • Virtu Financial reported no remaining Skye Bioscience position as of Q2 2025 after selling out during the quarter.
  • Virtu Financial sold 1,626 Skye Bioscience shares in Q2 2025, an estimated $21K.
  • Virtu Financial first reported a position in Skye Bioscience in Q4 2024 and held it in 2 quarters.
  • Virtu Financial's Skye Bioscience position peaked at $29K in Q4 2024.
  • 55 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2025.

Based on Virtu Financial's 13F filing for Q2 2025, filed 12 Aug 2025.